Search - tctmd.com

Displaying 61 - 80 of 81

Sort: Relevancy | Date

News Daily News

‘Inadvertent Reversal’ of Late Mortality Data Flips Advantage From Paclitaxel Zilver PTX Stent in PAD to PTA

L.A. McKeown

February 20, 2019

News Daily News

Mortality Data ‘Inadvertently Omitted’ From IN.PACT Analysis of Paclitaxel-Coated Balloons

L.A. McKeown

February 19, 2019

News Daily News

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

L.A. McKeown

February 13, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2019

Caitlin E. Cox

January 31, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Daily News

FDA Alerts Doctors to Potential Late Risks With Paclitaxel-Coated Balloons and Stents in PAD

Michael O'Riordan

January 17, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2018

Caitlin E. Cox

January 01, 2019

News Features

Top News in Endovascular Therapy: 2018

L.A. McKeown

December 28, 2018

News Daily News

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

L.A. McKeown

December 17, 2018

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

News Conference News AHA 2016

AHA/ACC Issue Updated PAD Guidelines

L.A. McKeown

November 14, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2016

Caitlin E. Cox

September 01, 2016

News Conference News TCT 2015

Boston Scientific Co-founder John Abele Recognized by TCT Career Achievement Award

October 12, 2015

News Industry News

Spectranetics Completes Enrollment in ILLUMENATE Pivotal Study to Assess Safety and Efficacy of Stellarex(TM) Drug-Coated Balloon Technology

July 29, 2015

News Daily News

RIBS IV: Los SLE Superan a los BRF en el Manejo de la Reestenosis Intra-Stent

L.A. McKeown

July 01, 2015

News Daily News

RIBS IV: EES Surpass DCB for Treatment of In-Stent Restenosis

L.A. McKeown

July 01, 2015

News Daily News

RIBS IV：EES 支架内再狭窄治疗效果超越 DCB

L.A. McKeown

July 01, 2015

News Daily News

LEVANT 2: Un BRF Supera a la Angioplastia con Balón Estándar al cabo de 1 Año en el Manejo de la Enfermedad Femoropoplítea

Yael L. Maxwell

June 26, 2015

News Daily News

LEVANT 2: DCB Beats Standard Balloon Angioplasty at 1 Year in Femoropopliteal Disease

Yael L. Maxwell

June 26, 2015

Advertisement

‘Inadvertent Reversal’ of Late Mortality Data Flips Advantage From Paclitaxel Zilver PTX Stent in PAD to PTA

Mortality Data ‘Inadvertently Omitted’ From IN.PACT Analysis of Paclitaxel-Coated Balloons

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

TCTMD’s Top 10 Most Popular Stories for January 2019

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

FDA Alerts Doctors to Potential Late Risks With Paclitaxel-Coated Balloons and Stents in PAD

TCTMD’s Top 10 Most Popular Stories for December 2018

Top News in Endovascular Therapy: 2018

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

AHA/ACC Issue Updated PAD Guidelines

TCTMD’s Top 10 Most Popular Stories for August 2016

Boston Scientific Co-founder John Abele Recognized by TCT Career Achievement Award

Spectranetics Completes Enrollment in ILLUMENATE Pivotal Study to Assess Safety and Efficacy of Stellarex(TM) Drug-Coated Balloon Technology

RIBS IV: Los SLE Superan a los BRF en el Manejo de la Reestenosis Intra-Stent

RIBS IV: EES Surpass DCB for Treatment of In-Stent Restenosis

RIBS IV：EES 支架内再狭窄治疗效果超越 DCB

LEVANT 2: Un BRF Supera a la Angioplastia con Balón Estándar al cabo de 1 Año en el Manejo de la Enfermedad Femoropoplítea

LEVANT 2: DCB Beats Standard Balloon Angioplasty at 1 Year in Femoropopliteal Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content